KSPHF:OTCMKTS
Kissei Pharmaceutical Co Ltd
24,50 US$
0,00%
(0,00) 1D
1 ოქტ, 10:21:43 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KSPHF...
Mkt. cap
176,63 მლრ.
Avg. vol.
20,00
Volume
0,00
52-wk high
31,90 US$
52-wk low
24,50 US$
Beta
13,94
Shares outstanding
46,54 მლნ.
No. of employees
2 ათ.
Mkt. cap
176,63 მლრ.
Avg. vol.
20,00
Volume
0,00
52-wk high
31,90 US$
52-wk low
24,50 US$
Beta
13,94
Shares outstanding
46,54 მლნ.
No. of employees
2 ათ.
News stories
From web sources and news partners
Simply Wall Street
·
12 წუთის წინ
Molgramostim Data Preview Could Be A Big Test For Savara Stock (SVRA)
Markets Media
·
16 წუთის წინ
HKEX Offers S&P 500 & HKEX Tech 100 Index
Benzinga
·
52 წუთის წინ
Jim Cramer Says ‘Stay In, Keep Buying’ as S&P 500 Surges 118% From 2022 Low — Nvidia Turned $10,000 Into
Yahoo Finance
·
5 საათის წინ
Citi Says S&P 500 Needs AI and Non-AI Stocks to Reach 8,100
Profile
Kissei Pharmaceutical is a pharmaceutical company based in Matsumoto, Nagano, Japan. Products discovered or developed by Kissei include:
Difelikefalin
Fostamatinib
Linzagolix
Mitiglinide
Remogliflozin etabonate
Silodosin
Tranilast
In March 2020, Kissei and CG Oncology, Inc. announced an exclusive license, development, and commercialization agreement for CG's oncolytic immunotherapy drug CG0070. The agreement covered Japan, South Korea, Taiwan, and other Asian countries, but not China. Wikipedia
About Kissei Pharmaceutical Co Ltd
CEOმუცუო კანზავა
Employees1,79 ათ.
Founded9 აგვ. 1946
HeadquartersMatsumoto, Nagano, იაპონია
SectorPharmaceutical industry
Websitekissei.co.jp